Menu
Věda a výzkum

Vybrané publikace

 

  1. KAISRLIKOVA, M.; KUNDRAT, D.; KORALKOVA, P.; TRSOVA, I.; LENERTOVA, Z.; VOTAVOVA, H.; DOSTALOVA MERKEROVA, M.; KREJCIK, Z.; VESELA, J.; VOSTRY, M.; SIMECKOVA, R.; STASTNA MARKOVA, M.; LAUERMANNOVA, M.; JONASOVA, A.; CERMAK, J.; DIVOKY, V.; BELICKOVA, M. Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms. International Journal of Cancer. 2024. doi.org/10.1002/ijc.34834.
     
  2. SESTAKOVA, S., SALEK, C., KUNDRAT, D., CEROVSKA, E.; VYDRA, J.; JEZISKOVA, I.; FOLTA, A.; MAYER, J.; CETKOVSKY, P.; REMESOVA, H.  MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia. Clin Epigenet 16, 17 (2024). doi.org/10.1186/s13148-024-01625-x
     
  3. CEROVSKA, E.; SALEK, C.; KUNDRAT, D.; SESTAKOVA, S.; PESEK, A.; BROZINOVA, I.; BELICKOVA, M.; REMESOVA, H. ABC transporters are predictors of treatment failure in acute myeloid leukaemia. Biomedicine and pharmacotherapy. 2024, vol. 170, no. January, art. no. 115930. ISSN 0753-3322.
     
  4. FUCHS, O. Targeting cereblon in hematologic malignancies. Blood reviews. 2023, vol. 57, no. [January], art. no. 100994. ISSN 0268-960X.
     
  5. TRSOVA, I.; HRUSTINCOVA, A.; KREJCIK, Z.; KUNDRAT, D.; HOLOUBEK, A.; STAFLOVA, K.; JANSTOVA, L.; VANIKOVA, S.; SZIKSZAI, K.; KLEMA, J.; RYSAVY, P.; BELICKOVA, M.; KAISRLIKOVA, M.; VESELA, J.; CERMAK, J.; JONASOVA, A.; DOSTAL, J.; FRIC, J.; MUSIL, J.; DOSTALOVA MERKEROVA, M. Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1. Molecular oncology. 2023, vol. 17, no. 12, s. 2565-2583. ISSN 1574-7891.
     
  6. BERNARD, E.; TUECHLER, H.; GREENBERG, P.L.; HASSERJIAN, R.P.; ARANGO OSSA, J.E.; NANNYA, Y.; DEVLIN, S.M.; CREIGNOU, M.; PINEL, P.; MONNIER, L.; GUNDEM, G.; MEDINA-MARTINEZ, J.S.; DOMENICO, D.; JÄDERSTEN, M.; GERMING, U.; SANZ, G.; VAN DE LOOSDRECHT, A.A.; KOSMIDER, O.; FOLLO, M.Y.; THOL, F.; ZAMORA, L.; PINHEIRO, R.F.; PELLAGATTI, A.; ELIAS, H.K.; HAASE, D.; GANSTER, C.; ADES, L.; TOBIASSON, M.; PALOMO, L.; DELLA PORTA, M.G.; TAKAORI-KONDO, A.; ISHIKAWA, T.; CHIBA, S.; KASAHARA, S.; MIYAZAKI, Y.; VIALE, A.; HUBERMAN, K.; FENAUX, P.; BELICKOVA, M.; ET AL. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM evidence. 2022, vol. 1, no. 7, nestr. ISSN 2766-5526.
     
  7. VOTAVOVA, H.; BELICKOVA, M. Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: immune‑mediated bone marrow failure syndromes (review). International journal of oncology. 2022, vol. 60, no. 1, art. no. 7. ISSN 1019-6439.
     
  8. DOSTALOVA MERKEROVA, M.; KLEMA, J.; KUNDRAT, D.; SZIKSZAI, K.; KREJCIK, Z.; HRUSTINCOVA, A.; TRSOVA, I.; LE, A.V.; CERMAK, J.; JONASOVA, A.; BELICKOVA, M. Noncoding RNAs and their response predictive value in azacitidine-treated patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes. Cancer genomics and proteomics. 2022, vol. 19, no. 2, s. 205-228. ISSN 1109-6535.
     
  9. ŠESTÁKOVÁ, Š.; CEROVSKÁ, E.; ŠÁLEK, C.; KUNDRÁT, D.; JEŽÍŠKOVÁ, I.; FOLTA, A.; MAYER, J.; RÁČIL, Z.; CETKOVSKÝ, P.; REMEŠOVÁ, H. A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel. Clinical epigenetics. 2022, vol. 14, no. 1, art. no. 22. ISSN 1868-7075.
     
  10. KAISRLIKOVA, M.; VESELA, J.; KUNDRAT, D.; VOTAVOVA, H.; DOSTALOVA-MERKEROVA, M.; KREJCIK, Z.; DIVOKY, V.; JEDLICKA, M.; FRIC, J.; KLEMA, J.; MIKULENKOVA, D.; STASTNA MARKOVA, M.; LAUERMANNOVA, M.; MERTOVA, J.; SOUKUPOVA MAALOUFOVA, J.; JONASOVA, A.; CERMAK, J.; BELICKOVA, M. RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS. Leukemia. 2022, vol. 36, no. 7, s. 1898-1906. ISSN 0887-6924.
     
  11. BERNARD, E.; NANNYA, Y.; HASSERJIAN, R.P.; DEVLIN, S.M.; TUECHLER, H.; MEDINA-MARTINEZ, J.S.; YOSHIZATO, T.; SHIOZAWA, Y.; SAIKI, R.; MALCOVATI, L.; LEVINE, M.F.; ARANGO, J.E.; ZHOU, Y.; SOLÉ, F.; CARGO, C.A.; HAASE, D.; CREIGNOU, M.; GERMING, U.; ZHANG, Y.; GUNDEM, G.; SARIAN, A.; VAN DE LOOSDRECHT, A.A.; JÄDERSTEN, M.; TOBIASSON, M.; KOSMIDER, O.; FOLLO, M.Y.; THOL, F.; PINHEIRO, R.F.; SANTINI, V.; KOTSIANIDIS, I.; BOULTWOOD, J.; SANTOS, F.P.S.; SCHANZ, J.; KASAHARA, S.; ISHIKAWA, T.; TSURUMI, H.; TAKAORI-KONDO, A.; KIGUCHI, T.; POLPRASERT, C.; BENNETT, J.M.; KLIMEK, V.M.; SAVONA, M.R.; BELICKOVA, M.; ET AL. Author correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (Nature Medicine, (2020), 26, 10, (1549-1556), 10.1038/s41591-020-1008-z). Nature Medicine. 2021, vol. 27, no. 3, s. 562. ISSN 1078-8956.
     
  12. VOTAVOVA, H.; URBANOVA, Z.; KUNDRAT, D.; DOSTALOVA MERKEROVA, M.; VOSTRY, M.; HRUBA, M.; CERMAK, J.; BELICKOVA, M. Modulation of the immune response by deferasirox in myelodysplastic syndrome patients. Pharmaceuticals. 2021, vol. 14, no. 1, art. no. 41. ISSN 1424-8247.
     
  13. FUCHS, O.; BOKOROVA, R. Preclinical studies of PROTACs in hematological malignancies. Cardiovascular & hematological disorders drug targets. 2021, vol. 21, no. 1, s. 7-22. ISSN 1871-529X.
     
  14. KORALKOVA, P.; BELICKOVA, M.; KUNDRAT, D.; DOSTALOVA MERKEROVA, M.; KREJCIK, Z.; SZIKSZAI, K.; KAISRLIKOVA, M.; VESELA, J.; VYHLIDALOVA, P.; STETKA, J.; HLAVACKOVA, A.; SUTTNAR, J.; FLODR, P.; STRITESKY, J.; JONASOVA, A.; CERMAK, J.; DIVOKY, V. Low plasma citrate levels and specific transcriptional signatures associated with quiescence of CD34+ progenitors predict Azacitidine therapy failure in MDS/AML patients. Cancers. 2021, vol. 13, no. 9, art. no. 2161. ISSN 2072-6694.
     
  15. DOSTÁLOVÁ MERKEROVÁ, M.; KREJČÍK, Z. Transposable elements and Piwi‑interacting RNAs in hemato‑oncology with a focus on myelodysplastic syndrome: review. International journal of oncology. 2021, vol. 59, no. 6, art. no. 105. ISSN 1019-6439.
     
  16. BERNARD, E.; NANNYA, Y.; HASSERJIAN, R.P.; DEVLIN, S.M.; TUECHLER, H.; MEDINA-MARTINEZ, J.S.; YOSHIZATO, T.; SHIOZAWA, Y.; SAIKI, R.; MALCOVATI, L.; LEVINE, M.F.; ARANGO, J.E.; ZHOU, Y.; SOLÉ, F.; CARGO, C.A.; HAASE, D.; CREIGNOU, M.; GERMING, U.; ZHANG, Y.; GUNDEM, G.; SARIAN, A.; VAN DE LOOSDRECHT, A.A.; JÄDERSTEN, M.; TOBIASSON, M.; KOSMIDER, O.; FOLLO, M.Y.; THOL, F.; PINHEIRO, R.F.; SANTINI, V.; KOTSIANIDIS, I.; BOULTWOOD, J.; SANTOS, F.P.S.; SCHANZ, J.; KASAHARA, S.; ISHIKAWA, T.; TSURUMI, H.; TAKAORI-KONDO, A.; KIGUCHI, T.; POLPRASERT, C.; BENNETT, J.M.; KLIMEK, V.M.; SAVONA, M.R.; BELICKOVA, M.; ET AL. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine. 2020, vol. 26, no. 10, s. 1549-1556. ISSN 1078-8956.
     
  17. HRUSTINCOVA, A.; KREJCIK, Z.; KUNDRAT, D.; SZIKSZAI, K.; BELICKOVA, M.; PECHERKOVA, P.; KLEMA, J.; VESELA, J.; HRUBA, M.; CERMAK, J.; HRDINOVA, T.; KRIJT, M.; VALKA, J.; JONASOVA, A.; MERKEROVA, M.D. Circulating small noncoding RNAs have specific expression patterns in plasma and extracellular vesicles in myelodysplastic syndromes and are predictive of patient outcome. Cells. 2020, vol. 9, no. 4, art. no. E794. ISSN 2073-4409.
     
  18. FUCHS, O.; BOKOROVA, R. Rationale of targeting protein cereblon as a potential strategy for cancer treatment. Drugs of the future. 2020, vol. 45, no. 5, s. 305-317. ISSN 0377-8282.
     
  19. DOSTALOVA MERKEROVA, M.; KREJCIK, Z.; SZIKSZAI, K.; KUNDRAT, D. Circular RNAs in hematopoiesis with a focus on acute myeloid leukemia and myelodysplastic syndrome. International journal of molecular sciences. 2020, vol. 21, no. 17, art. no E5972. ISSN 1422-0067.
     
  20. ŠÁLEK, C.; VYDRA, J.; CEROVSKÁ, E.; ŠESTÁKOVÁ, Š.; RANSDORFOVÁ, Š.; VÁLKOVÁ, V.; CETKOVSKÝ, P.; REMEŠOVÁ, H. WT1 expression in peripheral blood at diagnosis and during the course of early consolidation treatment correlates with survival in patients with intermediate and poor-risk acute myeloid leukemia. Clinical lymphoma myeloma & leukemia. 2020, vol. 20, no. 12,s. e998-e1009. ISSN 2152-2650.
     
  21. SZIKSZAI, K.; KREJCIK, Z.; KLEMA, J.; LOUDOVA, N.; HRUSTINCOVA, A.; BELICKOVA, M.; HRUBA, M.; VESELA, J.; STRANECKY, V.; KUNDRAT, D.; PECHERKOVA, P.; CERMAK, J.; JONASOVA, A.; DOSTALOVA MERKEROVA, M. LncRNA profiling reveals that the deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 is associated with higher-risk myelodysplastic syndrome. Cancers. 2020, vol. 12, no. 10, art. no. 2726. ISSN 2072-6694.
     

 


Rychlý kontakt

Náměstek pro vědu a výzkum
Tel:+420 221 977 305

Zástupkyně náměstka
Tel:+420 221 977 648

Sekretariát
Tel:+420 221 977 144

Telefonní seznam ÚHKT


Provozní doba

Ambulance
Po – Pá: 7:00–18:00

Denní nemocnice
Víkendy: 9:00–13:00

Dárci
Po – Pá: 7:00–10:30

Návštěvy
Lůžkové oddělení
Po – Pá: 13:00–18:00

JIP a Transplantační jednotka
Po – Pá: 14:00–17:00

Kudy k nám

map

Ústav hematologie a krevní transfuze
U Nemocnice 2094/1
128 00 Praha 2

Nejbližší stanice metra: Karlovo náměstí (linka B)

Nejbližší stanice tramvaje: Karlovo náměstí (10, 16, 22), Moráň (3, 6, 10, 16, 18, 24)

Nejbližší stanice autobusu: U nemocnice (148), Karlovo náměstí (176)

Jak se k nám dostanete

×

Omezení návštěv

Do odvolání omezení návštěv

Z důvodu vysokého výskytu respiračních onemocnění platí do odvolání omezení návštěv a to 1 osoba denně na 20 minut. Po celou dobu návštěvy musí mít návštěvník i pacient nasazen FFP2 respirátor.

Vstup do ambulancí i na všechna oddělení pouze s FFP2 respirátorem.

Děkujeme za pochopení.

Zavřít
×

No visits

No visits until further notice

Medical facility managers may prohibit visits to the locally worsened epidemiological situation in the workplace, always in consultation.

Thank you for your understanding.

Zavřít
×

IHBT

The Institute of Hematology and Blood Transfusion is an expanding centre offering state‑of‑the art medicine and top-notch research, as well as a friendly and safe organization for both patients and personnel. Our mission – the meaning of existence of the IHBT – is to care, treat, educate and research.

Zavřít